145 related articles for article (PubMed ID: 18814765)
21. The endocannabinoid system as a novel approach for managing obesity.
Lillo JL
J Am Osteopath Assoc; 2007 Apr; 107(4 Suppl 2):S12-20. PubMed ID: 17784530
[TBL] [Abstract][Full Text] [Related]
22. Rimonabant improves weight and glycaemic control: first oral antidiabetic therapy in newly diagnosed type 2 diabetics.
Cardiovasc J Afr; 2008; 19(5):282-3. PubMed ID: 18997994
[No Abstract] [Full Text] [Related]
23. Rimonabant hydrochloride: an investigational agent for the management of cardiovascular risk factors.
Cox SL
Drugs Today (Barc); 2005 Aug; 41(8):499-508. PubMed ID: 16234873
[TBL] [Abstract][Full Text] [Related]
24. Potential role of the endocannabinoid receptor antagonist rimonabant in the management of cardiometabolic risk: a narrative review of available data.
Bronander KA; Bloch MJ
Vasc Health Risk Manag; 2007; 3(2):181-90. PubMed ID: 17580728
[TBL] [Abstract][Full Text] [Related]
25. Endocannabinoid system and cardiometabolic risk.
Saavedra LE
Clin Pharmacol Ther; 2007 Nov; 82(5):591-4. PubMed ID: 17898706
[TBL] [Abstract][Full Text] [Related]
26. The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes.
Gary-Bobo M; Elachouri G; Scatton B; Le Fur G; Oury-Donat F; Bensaid M
Mol Pharmacol; 2006 Feb; 69(2):471-8. PubMed ID: 16282221
[TBL] [Abstract][Full Text] [Related]
27. Effect of rimonabant, the cannabinoid CB1 receptor antagonist, on peripheral nerve in streptozotocin-induced diabetic rat.
Liu WJ; Jin HY; Park JH; Baek HS; Park TS
Eur J Pharmacol; 2010 Jul; 637(1-3):70-6. PubMed ID: 20406631
[TBL] [Abstract][Full Text] [Related]
28. Diabetes: assessing the pipeline.
Lebovitz H
Atheroscler Suppl; 2006 Apr; 7(1):43-9. PubMed ID: 16504599
[TBL] [Abstract][Full Text] [Related]
29. Rehashing endocannabinoid antagonists: can we selectively target the periphery to safely treat obesity and type 2 diabetes?
Patti ME
J Clin Invest; 2010 Aug; 120(8):2646-8. PubMed ID: 20664166
[TBL] [Abstract][Full Text] [Related]
30. Rimonabant: endocannabinoid inhibition for the metabolic syndrome.
Wierzbicki AS
Int J Clin Pract; 2006 Dec; 60(12):1697-706. PubMed ID: 17109677
[TBL] [Abstract][Full Text] [Related]
31. Rimonabant as a novel therapeutic option for nonalcoholic steatohepatitis.
Banasch M; Goetze O; Schmidt WE; Meier JJ
Liver Int; 2007 Oct; 27(8):1152-5. PubMed ID: 17845546
[No Abstract] [Full Text] [Related]
32. What is the potential role of cannabinoid-1 receptor blockade in glucose and lipid management?
Jensen MD
Am J Med; 2007 Sep; 120(9 Suppl 1):S25-31; discussion S31-2. PubMed ID: 17720358
[TBL] [Abstract][Full Text] [Related]
33. [Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: overview of RIO studies].
Scheen AJ; Van Gaal LG; Després JP; Pi-Sunyer X; Golay A; Hanotin C
Rev Med Suisse; 2006 Aug; 2(76):1916-23. PubMed ID: 16972542
[TBL] [Abstract][Full Text] [Related]
34. The endocannabinoid system: a new target for the regulation of energy balance and metabolism.
Després JP
Crit Pathw Cardiol; 2007 Jun; 6(2):46-50. PubMed ID: 17667864
[TBL] [Abstract][Full Text] [Related]
35. [Rimonabant helps in overweight patients with multiple cardiovascular risk factors such as type 2 diabetes].
Golay A
Rev Med Suisse; 2008 Aug; 4(168):1828. PubMed ID: 18814768
[No Abstract] [Full Text] [Related]
36. Rimonabant--a selective CB1 antagonist.
Boyd ST; Fremming BA
Ann Pharmacother; 2005 Apr; 39(4):684-90. PubMed ID: 15755787
[TBL] [Abstract][Full Text] [Related]
37. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.
Van Gaal LF; Rissanen AM; Scheen AJ; Ziegler O; Rössner S;
Lancet; 2005 Apr 16-22; 365(9468):1389-97. PubMed ID: 15836887
[TBL] [Abstract][Full Text] [Related]
38. Exenatide and rimonabant: new treatments that may be useful in the management of diabetes and obesity.
Green JB; Feinglos MN
Curr Diab Rep; 2007 Oct; 7(5):369-75. PubMed ID: 18173970
[TBL] [Abstract][Full Text] [Related]
39. Reduced food intake is the major contributor to the protective effect of rimonabant on islet in established obesity-associated type 2 diabetes.
Jin SM; Oh BJ; Lee S; Choi JM; Yang SJ; Park SW; Kim KW; Kim JH; Park CY
Yonsei Med J; 2013 Sep; 54(5):1127-36. PubMed ID: 23918561
[TBL] [Abstract][Full Text] [Related]
40. Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: safety, tolerability, and therapeutic potential.
Steinberg BA; Cannon CP
Am J Cardiol; 2007 Dec; 100(12A):27P-32P. PubMed ID: 18154743
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
